A comparison of the additive efficacy of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome.

A comparison of the additive efficacy of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome. - Additive effect of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021086

Enrollment

Registered

2016-03-01

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma-COPD overlap syndrome

Interventions

Additive admionistration of Umeclidinium bromide on fluticasone furoate/vilanterole in patients with asthma-COPD overlap syndrome Patients are divided in 2 groups. In group A, firstly 4 week treatmen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: stable asthma-COPD overlap syndrome

Exclusion criteria

Exclusion criteria: unstable asthma-COPD overlap syndrome

Design outcomes

Primary

Measure	Time frame
Improvement of respiratory functions	—

Secondary

Measure	Time frame
Improvement of quality of life	—

Countries

Japan

Contacts

Public ContactYoshihisa Ishiura

Toyama City Hospital Respiratory Medicine

ishiura@tch.toyama.toyama.jp076-422-1112

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026